University of Michigan Rogel Cancer Center
umich.eduLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
318
Active
61
Phase 3
2
Total enrollment
23,275
Pipeline matrix
Showing 40 of 52 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Paclitaxel | — | — | — | 13 | |||
| Pembrolizumab | — | — | — | — | 9 | ||
| Mycophenolate Mofetil | — | — | — | — | 3 | ||
| Olaparib | — | — | — | — | — | 3 | |
| Temozolomide | — | — | — | — | 3 | ||
| Cyclophosphamide | — | — | — | — | — | 2 | |
| Leuprolide | — | — | — | — | — | 2 | |
| Prednisone | — | — | — | — | — | 2 | |
| Carboplatin | — | — | — | — | 17 | ||
| Nivolumab | — | — | — | — | 11 | ||
| Tacrolimus | — | — | — | — | — | 5 | |
| Ipilimumab | — | — | — | — | 5 | ||
| Bortezomib | — | — | — | — | 4 | ||
| Ruxolitinib | — | — | — | — | 4 | ||
| Vorinostat | — | — | — | — | 3 | ||
| Methotrexate | — | — | — | — | — | 3 | |
| Lenalidomide | — | — | — | — | — | 3 | |
| Pacritinib | — | — | — | — | 3 | ||
| Enzalutamide | — | — | — | — | 2 | ||
| ESK981 | — | — | — | — | — | 2 | |
| Sirolimus | — | — | — | — | — | 1 | |
| Iron chelation | — | — | — | — | — | 1 | |
| Potato Resistant Starch | — | — | — | — | — | 1 | |
| AZD6738 | — | — | — | — | — | 1 | |
| Niraparib | — | — | — | — | — | 1 | |
| Abiraterone Acetate | — | — | — | — | — | 1 | |
| Daratumumab | — | — | — | — | — | 1 | |
| Platinum based chemotherapy | — | — | — | — | — | 1 | |
| Chemoradiation | — | — | — | — | — | 1 | |
| Mogamulizumab | — | — | — | — | — | 1 | |
| Enfortumab vedotin | — | — | — | — | — | 1 | |
| Ivonescimab | — | — | — | — | — | 1 | |
| APG-115 | — | — | — | — | — | 1 | |
| Adjuvant temozolomide | — | — | — | — | — | 1 | |
| Starch, Potato | — | — | — | — | — | 1 | |
| Goserelin | — | — | — | — | — | 1 | |
| Lenvatinib | — | — | — | — | — | 1 | |
| Abiraterone | — | — | — | — | — | 1 | |
| Androgen Deprivation Therapy | — | — | — | — | — | 1 | |
| Cisplatin | — | — | — | — | 12 |
12 more active programs hidden
Next readouts
- 2023-01-26
- 2024-05-02
- 2025-01-06
- 2025-01-08
- 2025-07-30
- 2026-01-19
- 2026-02-21
- 2026-05-02
- 2026-08
- 2026-10
Top conditions
- Breast Cancer32
- Prostate Cancer28
- Pancreatic Cancer12
- Multiple Myeloma11
- Bladder Cancer9
- Colorectal Cancer7
- Head and Neck Cancer7
- Cancer6
Frequently asked questions about University of Michigan Rogel Cancer Center
- How many clinical trials does University of Michigan Rogel Cancer Center have on ClinicalTrials.gov?
- University of Michigan Rogel Cancer Center is listed as the lead sponsor on 318 clinical trials in ClinicalTrials.gov, 61 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Michigan Rogel Cancer Center's trials are in Phase 3?
- 2 of University of Michigan Rogel Cancer Center's trials are in Phase 3, spread across 52 active drug programs.
- What therapeutic areas does University of Michigan Rogel Cancer Center focus on?
- University of Michigan Rogel Cancer Center's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Prostate Cancer, Pancreatic Cancer, Multiple Myeloma, Bladder Cancer.
- When are University of Michigan Rogel Cancer Center's next clinical trial readouts?
- University of Michigan Rogel Cancer Center has 10 upcoming primary-completion readouts tracked here; the soonest is “Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)”, expected around 2023-01-26.